Denali's Alzheimer's drug faces setback at the FDA after agency slaps clinical hold on human trial start
Denali Therapeutics was once a Cinderella story in neurology with high expectations on a platform it thinks could offer much greater brain penetration. Since then, that reputation has dimmed somewhat — and a new clinical hold won’t make any new fans.
The FDA has placed a clinical hold on Denali’s IND for DNL919, an Alzheimer’s candidate targeting the protein coding gene TREM2, the biotech announced in a terse statement Thursday.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 158,500+ biopharma pros reading Endpoints daily — and it's free.